Collectively, CRP remains an important metabolic biomarker post-treatment, highly prone to worsening over time that should be closely monitored throughout survivorship, in addition to insulin resistance, especially among obese, insulin resistant breast cancer survivors. This evidence concerns the gene CRP and breast carcinoma.